RxDoctor Payments Data

Maher Al-Sheikh, MD

Family Medicine · Okemos, MINPI 1467565440

Payments from drug & device makers

$4,883in general payments, 2019–2025

Across 258 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$703
  • AbbVie$445
  • Lilly USA, LLC$411
  • Novo Nordisk$370
  • Pfizer$234
  • Medtronic$224
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$4,883100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,883 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$64,038
Medicare patients
112
Services billed
975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide46$85,684
EliquisApixaban72$75,615
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$59,896
JardianceEmpagliflozin27$40,678
XareltoRivaroxaban28$32,416
JanuviaSitagliptin Phosphate16$25,578
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,794
Tresiba Flextouch U-100Insulin Degludec17$8,367
TresibaInsulin Degludec11$8,162
Celecoxib186$7,373
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen316$5,875
Albuterol Sulfate HfaAlbuterol Sulfate141$5,756
Omeprazole314$5,562
Atorvastatin Calcium382$5,432
Levothyroxine Sodium416$5,094

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$411$85,68446 claims
PfizerEliquis$234$75,61572 claims
GSKTrelegy Ellipta, Arnuity Ellipta$703$62,55674 claims
Boehringer IngelheimJardiance$79$40,67827 claims
Johnson & JohnsonXarelto$100$32,41628 claims
AstraZenecaBreztri Aerosphere$202$8,79414 claims
Novo NordiskTresiba$370$8,16211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Okemos

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →